Name

The Lundquist Institute

Legal name

The Lundquist Institute for Biomedical Innovation

Website

https://lundquist.org

Company type

Private

Founded year

1952

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Professional, Scientific, and Technical Services (541)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Educational Services (8200)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

akta.pro secondary industries

Microbiology & Infectious Disease Testing (Trial Support) (HLAGAEAF), Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA), Medical, Clinical & Biomedical Scholarly Publishing (EDAGAFAB), General Infectious Disease (HLAKAGAA)

Keywords

• Biomedical research
• Clinical trials
• Translational science
• Technology licensing
• Community health programs

Headquarters

HQ city

Torrance

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Federal Research Grants: Primary funding from NIH and other federal agencies. The institute received nearly $70 million in NIH grants in 2024 and additional funding from CIRM. NIH grants support research across all four innovation hubs.
2. Foundation Grants: Funding from private foundations including Conrad N. Hilton Foundation ($3.44M), Parsons Foundation ($100,000), and Thomas J. Beatson Jr. Foundation ($287,500). These grants support specific programs like Medical-Financial Partnership and research initiatives.
3. Technology Licensing and Royalties: Revenue from licensing technologies to industry partners and spin-off companies. Over $100M in technology transfer revenue in the past decade from 300+ patents issued and 840+ patent applications.
4. Industry-Sponsored Research: Sponsored research agreements, collaboration agreements, and clinical trial funding from pharmaceutical and biotech companies. TLI conducts industry-sponsored and investigator-led clinical trials.
5. Philanthropic Donations: Tax-deductible donations from individuals, corporate giving, and planned giving programs. Federal Tax ID: 95-2138184. The institute runs donation campaigns with matching opportunities.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

The Lundquist Institute is a nonprofit biomedical research organization that conducts translational research across four Innovation Hubs (Advanced Therapeutics & Biomedical Technologies, Infectious Diseases & Immunology, Systems Medicine & Precision Prevention, and Translational Science & Population Health). It runs investigator-led and industry-sponsored clinical trials, licenses patented technologies to industry partners, and operates community health programs including WIC services across South Los Angeles.

Product overview

The Lundquist Institute is a nonprofit biomedical research organization offering a portfolio of research services, clinical trials, and community health programs. The core offerings include clinical research conducted through 600+ active studies and 100+ clinical trials, supported by four Innovation Hubs (Advanced Therapeutics & Biomedical Technologies, Infectious Diseases & Immunology, Systems Medicine & Precision Prevention, Translational Science & Population Health). Educational programs include the STAR High School Program (since 1978) and Postdoctoral Fellows Program. Community programs encompass the Women, Infants, and Children (WIC) Program (serving 63,700+ participants monthly), Medical-Financial Partnership, and South Los Angeles Health Projects. The institute also supports commercialization through BioLabs incubator (18,000 sq ft) and has spun off companies including QT Medical (FDA-approved PCA 500 ECG device) and Vitalex Biosciences (VXV-01 fungal vaccine in Phase 1 trials). Several FDA-approved technologies have originated from the institute including Aldurazyme, Endari, Kybella, and Tepezza.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trials Services Contracted clinical trial services for pharmaceutical and biotech industry sponsors and investigator-initiated studies across multiple therapeutic areas, leveraging access to diverse patient populations at Harbor-UCLA Medical Center.
• BioLabs at The Lundquist Institute Onsite life science incubator offering 18,000 square feet of flexible laboratory and co-working spaces for bioscience startups.
• Women, Infants, and Children (WIC) Program California's third-largest WIC program operating across 11 South Los Angeles locations, serving over 63,700 participants monthly with supplemental foods, nutrition education, and breastfeeding support.
• Medical-Financial Partnership (MFP) Community program integrating financial coaching and social support into healthcare settings in Los Angeles County, addressing health disparities linked to poverty through the Benefits Explorer Tool (BET).
• South Los Angeles Health Projects (SLAHP)

Quantifiable outcome

• $100M+ in technology transfer revenue in the past decade
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Nine partnerships are on record, tiered major, core and minor.

• Trammell Crow Co.majorStrategic or Co-development PartnerDevelopment partnership for 15-acre biotech park (TLI BioCenter) to support companies graduating from the BioLabs incubator. This is a long-term strategic initiative to expand the institute's innovation ecosystem and commercialization infrastructure.
• Harbor-UCLA Medical CentercoreStrategic or Co-development PartnerClinical partnership providing research infrastructure, patient access, and clinical trial capabilities. The institute is located on the Harbor-UCLA campus in Torrance, California.
• BioLabscoreChannel Partner/ Reseller/ Distributor18,000 sq ft onsite life science incubator providing flexible workspaces for bioscience startups to develop and grow innovations emerging from TLI research.
• David Geffen School of Medicine at UCLAcoreStrategic or Co-development PartnerMany TLI investigators hold faculty appointments at UCLA, providing access to academic resources, training programs, and research collaboration opportunities.
• UCLA CTSI (Clinical and Translational Science Institute)coreStrategic or Co-development PartnerUCLA CTSI at The Lundquist Institute accelerates clinical and translational research, providing infrastructure, services, and training for efficient research operations.
• Vitalex BiosciencesmajorStrategic or Co-development PartnerT LI spin-off company developing a dual-antigen cross-kingdom vaccine targeting hospital-acquired infections caused by multidrug resistant Candida strains and Gram-negative bacteria. Advancing through Phase 1 trials under $40 million NIH/NIAID contract.
• QT MedicalmajorStrategic or Co-development PartnerT LI spin-off company developing the first portable, medical grade mini ECG device (PCA500). TLI out-licensed the technology for commercialization.
• BDIminorStrategic or Co-development PartnerT LI spin-off company pioneering image analytics to diagnose diseases like osteoporosis from routine, existing medical images.
• AstraZenecaminorStrategic or Co-development PartnerT LI at Harbor-UCLA Medical Center administered the first Phase 3 AstraZeneca trial injection, demonstrating industry partnership capabilities.

Scale indicators14 records

Recent moves7 records

Expansion highlights4 records

Regional players

• City of Hope Comprehensive Cancer Center: California-based nonprofit biomedical research and clinical care organization with comparable NIH funding, clinical trial infrastructure, biotech spin-offs, and a translational research mission — overlapping in regional scope and operating model.

Emerging players

• La Jolla Institute for Immunology: Nonprofit research institute specializing in immunology and infectious disease — overlapping directly with TLI's Infectious Diseases & Immunology Innovation Hub and its translational clinical trial capability.

Direct peers

• Wistar Institute: Nonprofit biomedical research institute in Philadelphia focused on cancer, immunology, and infectious disease. Comparable NIH grant-funded, university-affiliated translational research model with active spin-off and licensing activity.
• Gladstone Institutes: UCSF-affiliated nonprofit research organization focused on cardiovascular, neurological, and immunological diseases. Comparable in academic medical-center affiliation, NIH funding model, and translational-to-commercial research mission.
• Sanford Burnham Prebys Medical Discovery Institute: Nonprofit biomedical research institute in La Jolla focused on translational research, drug discovery, and technology commercialization — directly comparable to TLI's four-hub translational model and tech transfer-driven revenue stream.

Broad incumbents

• Allen Institute: Philanthropically funded nonprofit research organization with active programs in immunology and brain science. Comparable in nonprofit translational research scale, mixed funding model, and institute-level research output.
• Cold Spring Harbor Laboratory: Nonprofit research and educational institution conducting cancer, neuroscience, and genomics research with a major NIH funding base. Comparable in scale, mixed research/education portfolio, and technology transfer activity.
• Whitehead Institute for Biomedical Research: MIT-affiliated nonprofit biomedical research institute with a similar structure of principal investigator-led labs, NIH funding, and active IP commercialization through biotech spin-outs.
• Salk Institute for Biological Studies: Nonprofit biomedical research institute in La Jolla, California conducting basic research in neuroscience, cancer, immunology, and plant biology. Similar nonprofit model with NIH funding and a portfolio of spin-off companies and licensed technologies.
• Scripps Research Institute: Large nonprofit biomedical research organization operating basic and translational science across multiple therapeutic areas with a similar NIH-grant and licensing-based funding model. Comparable in scale, structure, and commercialization track record.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/the_lundquist
• Facebookfacebook.com/thelundquistinstitute

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Lundquist Institute